Toxic epidermal necrosis - Nekrożi Epidermali Tossika
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Telf karatteristiku tal-ġilda ta' Nekrożi Epidermali Tossika (Toxic epidermal necrosis)
References
Stevens-Johnson Syndrome (SJS) u Toxic Epidermal Necrolysis (TEN) huma kundizzjonijiet rari fejn il-ġilda tesperjenza nekrożi estensiva u tixrid. F'termini ta 'trattament, cyclosporine huwa effettiv ħafna għal SJS, filwaqt li taħlita ta' immunoglobulina ġol-vini (IVIg) u kortikosterojdi taħdem l-aħjar għal każijiet ta 'SJS u TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN.
Toxic epidermal necrolysis (TEN) hija reazzjoni serja tal-ġilda kkawżata minn ċerti mediċini u attività tas-sistema immuni, li tirriżulta f'distakk fuq skala kbira tas-saff tal-ġilda ta 'barra (epidermide) , li taffettwa aktar minn 30% tal-wiċċ tal-ġisem. TEN għandu rata ta 'mortalità ta' aktar minn 20%, ħafna drabi minħabba infezzjonijiet u diffikultajiet biex tieħu n-nifs. It-twaqqif tal-medikazzjoni li tikkawża r-reazzjoni, l-għoti ta 'kura ta' appoġġ, u l-użu ta 'trattamenti addizzjonali jistgħu jtejbu r-riżultat. Studji reċenti wrew li mediċini bħal cyclosporine, inibituri alfa tal-fattur tan-nekrożi tat-tumur, u taħlita ta 'globulina immuni ġol-vini u kortikosterojdi jistgħu jkunu ta' għajnuna, ibbażati fuq provi kkontrollati randomised u analiżi ta 'studji multipli.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
Toxic epidermal necrolysis (TEN) is a serious skin reaction caused by certain medications and immune system activity, resulting in large-scale detachment of the outer skin layer (epidermis), affecting more than 30% of the body's surface. TEN has a mortality rate of over 20%, often due to infections and breathing difficulties. Stopping the medication causing the reaction, providing supportive care, and using additional treatments can improve the outcome. Recent studies have shown that drugs like cyclosporine, tumor necrosis factor alpha inhibitors, and a combination of intravenous immune globulin and corticosteroids can be helpful, based on randomized controlled trials and analyses of multiple studies.
Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed.
L-aktar kawża komuni hija ċerti mediċini bħal lamotrigine, carbamazepine, allopurinol, antibijotiċi sulfonamide, u nevirapine. Fatturi ta' riskju jinkludu l-HIV u l-lupus erythematosus sistemiku. It-trattament tipikament iseħħ fl-isptar bħal f'unità tal-ħruq jew unità tal-kura intensiva.
○ Trattament
Din hija marda serja, għalhekk jekk ix-xufftejn jew il-ħalq tiegħek jiġu affettwati jew il-ġilda tiegħek titfa' nfafet, ara lit-tabib tiegħek kemm jista' jkun malajr.
Drogi suspettużi għandhom jitwaqqfu. (eż. antibijotiċi, mediċini anti-infjammatorji mhux sterojdi)